Ascendis Pharma Stock Price, News & Analysis

Ascendis Pharma A/S (Nasdaq: ASND) announced significant advancements in its investigational product candidate TransCon PTH for adult hypoparathyroidism, showcasing Phase 2 and Phase 3 trial data at ENDO 2022. Dr. Aliya Khan reported that the PaTHway Trial highlighted a majority of treated patients achieving disease control, including normalized serum calcium and independence from conventional therapy. The treatment was well-tolerated. These presentations aim to reshape the treatment paradigm for hypoparathyroidism and underline Ascendis' commitment to innovative therapies.

Ascendis Pharma has announced new leadership appointments in its Endocrinology commercial team. Joe Kelly is appointed Head of U.S. Commercial, while Scott A. Holmes takes on the role of Head of Global Commercial Strategy. This follows the retirement of Jesper Høiland, who will continue as a senior advisor. The team aims to enhance U.S. market leadership for SKYTROFA and prepare for upcoming TransCon product launches. Despite the leadership change, the company focuses on leveraging its TransCon technologies to develop innovative therapies.

Ascendis Pharma A/S announced positive results from VISEN Pharmaceuticals' Phase 3 trial of TransCon™ hGH for pediatric growth hormone deficiency (GHD) in China. The trial met its primary endpoint, demonstrating significantly greater annualized height velocity at 52 weeks (p=0.0010) compared to daily growth hormone treatment. This result aligns with previous multinational trial outcomes, confirming the safety and efficacy of TransCon hGH. The treatment is now approved in the U.S. and EU. The CEO praised VISEN for its achievement, underscoring TransCon technology's global applicability.

Ascendis Pharma (ASND) reported strong Phase 3 trial results for its TransCon PTH therapy, potentially positioning it as the first replacement therapy for adults with hypoparathyroidism. The company anticipates U.S. FDA submission by Q3 2022 and EU MAA submission by Q4 2022. First-quarter revenue surged to €6.8 million, up from €0.7 million, mainly driven by SKYTROFA sales. However, the net loss widened to €125.5 million, or €2.21 per share. Ascendis ended Q1 2022 with €1,065 million in cash, bolstering its investment potential for growth and sustainability.

Ascendis Pharma A/S (Nasdaq: ASND) will attend the BofA Securities 2022 Healthcare Conference on May 12, 2022, in Las Vegas, NV. Company executives are set to participate in a fireside chat from 1:40-2:10 p.m. ET. A live webcast will be accessible on their website, with a replay available for 30 days post-event. Ascendis aims to leverage its platform technology to develop new therapies, focusing on making a significant impact in patients' lives.

Ascendis Pharma A/S (Nasdaq: ASND) has scheduled a conference call for May 11, 2022, at 4:30 p.m. ET to discuss its first quarter financial results. The event will provide an update on the company's operations and financial performance. Interested parties can join via a live webcast on Ascendis Pharma's website, with a replay available afterward for 30 days. Ascendis Pharma focuses on using its TransCon technologies to develop innovative therapies aimed at improving patient outcomes.

Ascendis Pharma A/S (Nasdaq: ASND) announced new clinical data presentations at four medical meetings in May 2022. Key highlights include Phase 3 results for children with growth hormone deficiency treated with TransCon hGH for 2.5 years, and findings on comorbidities in adults with growth hormone deficiency. At the PES 2022 meeting, an oral presentation will detail the efficacy and safety of lonapegsomatropin in children. Additionally, the company’s FDA-approved treatment, SKYTROFA, will be showcased. This data signifies the expansion of Ascendis’ endocrinology portfolio.

Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of a private offering of US$500 million in 2.25% convertible senior notes due 2028, set to settle on March 29, 2022. An additional US$75 million may be purchased by initial buyers within 13 days. The notes will accrue interest semi-annually and are convertible into ADSs at a rate of 6.0118 ADSs per US$1,000 principal. The net proceeds, estimated at approximately US$485 million, will support various developmental activities including commercialization of TransCon hGH and clinical development of other products.

Ascendis Pharma A/S (Nasdaq: ASND) has announced a private offering of US$500,000,000 in convertible senior notes due 2028. The offering is aimed at qualified institutional buyers under Rule 144A and includes an option for initial purchasers to buy an additional US$75,000,000 in notes. The notes will accrue interest semi-annually and are convertible into Ascendis Pharma's American Depositary Shares (ADSs). Proceeds will fund the repurchase of up to 1 million ADSs and support the development of various therapeutics, including TransCon hGH and oncology programs.